Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Axsome Therapeutics, Inc

AXSM

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Last trade $135.92
Day change -$1.09 (-0.80%)
Day range $132.30 – $137.91
Volume 217,299
Market cap $7.21B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$7.21B
Price / earnings
—
Price / book
68.35×
Price / sales
8.33×
EV / sales
8.19×
EV / EBITDA
-49.19×

Profitability

Earnings per share
-$2.99
Return on assets
-19.02%
Return on equity
-149.19%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.87×
Current ratio
1.42×
Quick ratio
1.34×
Cash ratio
0.62×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$82.61M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for AXSM, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$259.69M$218.38M$191.2M$196M$170.99M$150.04M$121.46M$118.77M
Cost of revenue$17.8M$13.56M$14.73M$12.33M$11.91M$13.45M$9.79M$10.51M
Gross profit$241.89M$204.81M$176.48M$183.67M$159.08M$136.59M$111.67M$108.25M
Selling, general and administrative$203.11M$208.14M$185M$169.3M$150.24M$130.28M$120.79M$113.27M
Research and development$50.62M$46.23M$52.68M$48.79M$40.16M$49.54M$44.79M$55.01M
Total operating expenses$252.96M$254.46M$239.84M$210.63M$205.19M$173.31M$168.66M$180.87M
Operating income-$11.07M-$49.65M-$63.36M-$26.96M-$46.11M-$36.71M-$56.98M-$72.62M
Interest expense-$1.72M-$1.54M$0$0-$1.12M-$1.83M$0$0
Income before taxes-$12.79M-$51.19M-$64.54M-$28.13M-$47.23M-$48.93M-$59.41M-$74.83M
Income taxes$88K$128K$0$430K$0-$960K$0$85K
Net income-$12.88M-$51.31M-$64.54M-$28.56M-$47.23M-$47.97M-$59.41M-$74.91M
Net income attributable to common shareholders-$12.88M-$51.31M-$64.54M-$28.56M-$47.23M-$47.97M-$59.41M-$74.91M
EBITDA-$9.33M-$47.91M-$61.67M-$25.24M-$44.38M-$35.01M-$55.26M-$70.88M
Basic earnings per share-$0.25-$0.99-$1.26-$0.56-$0.94-$0.97-$1.22-$1.54
Diluted earnings per share-$0.25-$0.99-$1.26-$0.56-$0.94-$0.97-$1.22-$1.54

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027?

Axsome Therapeutics and Moderna represent different biotech investment profiles. Axsome shows strong 54% revenue growth with three marketed drugs and a narrowing path to profitability, trading at conservative valuations (41x forward P/E). Moderna, despite its revolutionary mRNA platform, faces declining COVID vaccine demand and significant losses ($2.8B net loss on $2.5B revenue), trading at a premium 249x forward P/E. The article recommends Axsome as the better 2027 buy due to superior valuation and near-term revenue visibility, while acknowledging Moderna's long-term potential.

The Motley Fool

Nasdaq Sell-Off: 2 Stocks to Buy on the Dip and Hold for 5 Years

Following a 5% Nasdaq decline after midterm elections, the article recommends two stocks for long-term investors: Shopify, which is leveraging AI-powered tools to drive strong revenue growth and capitalize on e-commerce expansion, and Axsome Therapeutics, a biotech company with strong performance from its depression and Alzheimer's drug Auvelity and a promising pipeline of new products.

Zacks Investment Research

Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates

Axsome Therapeutics (AXSM) reported a quarterly loss of $0.25 per share, beating consensus estimates of $0.69 loss by 63.77%, with revenues of $259.69 million exceeding expectations by 5.37%. However, the stock has underperformed the market, declining 20.9% year-to-date versus the S&P 500's 10.7% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

The Motley Fool

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Axsome Therapeutics has demonstrated steady quarter-over-quarter revenue growth, surpassing Moderna's quarterly revenue by Q2 2026 despite starting from a much smaller base. Meanwhile, Moderna has experienced significant revenue volatility, with sharp declines following peaks, largely due to reduced COVID-19 vaccine adoption and underperforming RSV vaccine sales. Axsome's three-drug portfolio shows promise with multiple clinical trials underway, while Moderna faces challenges from overreliance on products that have lost market traction.

Zacks Investment Research

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Rhythm Pharmaceuticals (RYTM) is expected to beat Q3 2026 earnings estimates with a positive Earnings ESP of +1.38% and Zacks Rank #3. The company is projected to report a quarterly loss of $0.68 per share (improved from $0.81 year-ago) with revenues of $84.47 million, up 64.7% year-over-year. The stock has beaten consensus EPS estimates in 3 of the last 4 quarters.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.